Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 737-748

  Nikol, S ^a   Huehns, T Y ^a   Krausz, E ^a   Armeanu, S ^a   Engelmann, M G ^a   Winder, D ^b   Salmons, B ^b   Hoefling, B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Bavarian Nordic GmbH   (Germany)

Author keywords

Angioplasty; Cecropin A; Gene therapy; Liposomes; Local drug delivery; Restenosis

Indexed keywords

ANTIINFECTIVE AGENT; CECROPIN A; LIPOSOME; PLASMID DNA; PROTEIN PRECURSOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BALLOON DILATATION; CATHETER; CONTROLLED STUDY; GENE TARGETING; INJECTION; INTIMA; NONHUMAN; PLASMID; PRIORITY JOURNAL; RESTENOSIS; SWINE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL DIVISION; CORONARY DISEASE; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; INJECTIONS; MUSCLE, SMOOTH, VASCULAR; PEPTIDES; PRODRUGS; RECURRENCE; SWINE;

ANIMALIA; MAMMALIA; SUIDAE; SUS SCROFA;

EID: 0032980746     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300888     Document Type: Article

References (40)

1. Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation 1993; 88: 1310-1323.
2. Schwartz RS, Holmes DJ, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-1293.
3. Bauters C, Isner JM. The biology of restenosis. Prog Cardiovasc Dis 1997; 40: 107-116.
4. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
5. Nikol S, Huehns TY, Hoefling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996; 123: 17-31.
6. Nikol S. Possible uses of gene therapy in reducing coronary restenosis. Heart 1997; 78: 426-428.
7. Simons M et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
8. Yang ZY et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Aand USA 1996; 93: 7905-7910.
9. Chang MW et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522.
10. Chang MW et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-2268.
11. Morishita R et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
12. Boman HG. Peptide antibiotics and their role in innate immunity. Ann Rev Immunol 1995; 13: 16-19.
13. Hernandez VP, Gerenday A, Fallon AM. Secretion of an inducible cecropin-like activity by cultured mosquito cells. Am J Trop Med Hyg 1994; 50: 440-447.
14. Javadpour MM et al. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996; 39: 3107-3113.
15. Jaynes JM et al. In vitro cytocidal effect of lytic peptides on several transformed mammalian cell lines. Pept Res 1989; 2: 157-160.
16. Moore AJ, Devine DA, Bibby MC. Preliminary experimental anticancer activity of cecropins. Pept Res 1994; 7: 265-269.
17. Winder D, Guenzburg WH, Erfle V, Salmons B. Expression of antimicrobial peptides has an antitumour effect in human cells. Biochem Biophys Res Commun 1998; 242: 608-612.
18. Nakata Y, Shionoya S. Vascular lesions due to obstruction of the vasa vasorum. Nature 1966; 212: 1258-1259.
19. Barker SGE et al. The adventitia and atherogenesis: removal initiates intimai proliferation in the rabbit which regresses on generation of a neoadventitia. Atherosclerosis 1994: 105: 131-144.
20. Huehns TY, Gonschior P, Hoefling B. Adventitia as a target for intravascular local drug delivery. Heart 1996; 75: 537-538.
21. Shi Y et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996; 94: 1655-1664.
22. Gonschior P, Goetz AE, Huehns TY, Hoefling B. A new catheter for prolonged local drug application. Coron Art Dis 1995; 6: 329-334.
23. Gonschior P et al. Comparison of local intravacular drug-delivery catheter systems. Am Heart J 1995; 130: 1174-1181.
24. Huehns T et al. Neointimal growth can be influenced by local adventitial gene manipulation via a needle injection catheter. Atherosclerosis (in press).
25. Innis MA, Gelfand DH. Optimization of PCRs. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds). PCR Protocols: A Guide to Methods and Applications. Academic Press: San Diego, 1990, pp 84-91.
26. Hoefling B, Huehns TY. Intravascular local drug delivery in restenosis. Eur Heart J 1995; 16: 437-440.
27. Wolinsky H, Thung SN. Use of the perforated balloon catheter to deliver concentrated heparin into the wall of normal canine artery. J Am Coll Cordial 1990; 15: 475-481.
28. Zhu N, Liggit N, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993; 261: 209-211.
29. Reszka R et al. Therapeutic and immunohistochemical evaluation of suicide gene transfer in a rat F98 glioblastoma model: liposomal approach versus viral delivery. Proceedings of the 3rd International workshop on Gene Transfer in Hematology and Oncology, Düsseldorf, Germany, 1997 (Abstr.).
30. Tahlil O et al. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997; 33: 181-187.
31. Nabel EG, Plautz G, Nabel GI. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285-1288.
32. Yonemitsu Y et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998; 82: 147-156.
33. Keogh MC et al. High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using cationic lipid-DNA complex. Gene Ther 1997; 4: 162-171.
34. Boman HG, Steiner H. Humoral immunity in Cecropia pupae. Curr Top Microbiol Immunol 1981; 94: 75-91.
35. Velasco M et al. Macrophage triggering with cecropin A and melittin derived peptides induces type II nitric oxide synthase expression. J Immunol 1997; 158: 4437-4443.
36. Hugosson M, Andreu D, Boman HG, Glaser E. Antibacterial peptides and mitochondrial presequences affect mitochondrial coupling, respiration and protein import. Eur J Biochem 1994; 223: 1027-1033.
37. Christensen B, Fink J, Merrifield RB, Mauzerall D. Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes. Proc Natl Acad Sci USA 1988; 85: 5072-5076.
38. Gazit E, Boman A, Boman HG, Shai Y. Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Biochemistry 1995; 34: 11479-11488.
39. Gazit E, Miller IR, Biggin PC, Sansom MSP. Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes. J Mol Biol 1996; 258: 860-870.
40. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus mediated gene transfer. Proc Natl Acad Sci USA 1987; 84: 156-160.